Which products are currently under development? 2025 will be a defining year for Caliway as we push ahead with key clin...
Could you please share some details of the company's investment plans, and new product development in the coming years?&...
What major plans are in store for the company (Asia Pacific region & global) in 2025? We’re going to keep del...
Chime Biologics has a vision to make biologics more accessible and affordable. How does this vision drive your day-to-da...
In an insightful interview with BioSpectrum Asia, Shaun Rothwell, CEO of EVÅŒQ Nano, reveals the transformative potent...
In a candid conversation with Ankit Kankar from BioSpectrum Asia, Dr. Boro Dropulić, Executive Director of Caring Cr...
Q: The usage of messenger RNA (mRNA) as novel active ingredient has attracted public attention in recent years, ...
On July 1, 2024, Cytiva significantly bolstered its leadership team by appointing Pierre-Alain Ruffieux as Chief...
Dr. Mohd Azizuddin bin Mohd Yussof, CT (IAC), Bsc. (Biomedical), MHealthSc. (Biomedical), PhD (Pathology) is the Directo...
Growing trends in healthcare digitalization are continuously transforming execution and practices in the ...
Lifescience Laboratory workflows, products and services are complex and can be difficult to manage due to long and strin...
The value-based care model is gaining momentum in the healthcare industry, and it is not hard to see why. After al...
Accessibility to quality healthcare is commonly regarded as a fundamental human right for every person. This is outlined...
Medicine and technology have made tremendous strides toward defeating one of the deadliest diseases of the world, despit...
The last two years saw a significant leap toward patient-centricity in the pharmaceutical space. In 2023, that trend wil...
What are the barriers to access that are impacting patient outcomes in managing antimicrobial resistance? Why do they ...
How crucial is the adaptation of next-generation TCR cell therapies for diagnostic and prophylactic purposes? TCR cell ...
Why does multiple sclerosis (MS) deserve attention and investment in APAC for the development of novel treatments? ...
In 2016, the Singapore government committed to a S$4 billion budget to drive research and commercialisation activities i...
Japanese headquartered Chugai Pharmaceutical has already developed world-class technologies for antibody engineeri...
Digital transformation in healthcare has been at breakneck speed since the outbreak of the COVID-19 pandemic. It took ju...
MiyaHealth, a Singapore based health technology company is transforming this space, to create a much needed data reposit...
With the innovation boom in Asia and many early-stage assets emerging, the time is ripe for Asian economies to establish...
What are the major plans in store for the new APAC hub at Singapore? For a company like Abcam which strongly believes t...
Global challenges are too large to tackle in isolation. The creation of new shared value in public research through acad...
